
WHO urges action as mosquito-borne chikungunya spreads
An estimated 5.6 billion people live in areas across 119 countries at risk from the virus, which can cause high fever, joint pain and long-term disability, Diana Rojas Alvarez, a WHO medical officer, told reporters in Geneva.
"We are seeing history repeating itself," she said, drawing parallels to the 2004-2005 epidemic, which affected nearly half a million people, primarily in small island territories, before spreading around the world.
The current surge began in early 2025, with major outbreaks in the same Indian Ocean islands which were previously hit, including Reunion, Mayotte and Mauritius.
An estimated one-third of Reunion's population has already been infected, Rojas Alvarez said. The virus is now spreading to countries such as Madagascar, Somalia and Kenya, and has shown epidemic transmission in Southeast Asia, including India.
Of particular concern is the increasing number of imported cases and recent local transmission within Europe.
There have been approximately 800 imported chikungunya cases in continental France since May 1, Rojas Alvarez said.
Twelve local transmission episodes have been detected in several southern French regions, meaning individuals were infected by local mosquitoes without having travelled to endemic areas. A case was also detected last week in Italy.
Chikungunya, for which there is no specific treatment and which is spread primarily by Aedes mosquito species, including the "tiger mosquito" which also transmits dengue, and Zika, can cause rapid and large outbreaks. As the mosquitoes bite in the daytime, prevention is key, through the use of insect repellent and long-sleeved clothing.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Age
9 hours ago
- The Age
Israel's leader claims no one in Gaza is starving. Data and witnesses disagree
Israeli Prime Minister Benjamin Netanyahu says no one in Gaza is starving: 'There is no policy of starvation in Gaza, and there is no starvation in Gaza. We enable humanitarian aid throughout the duration of the war to enter Gaza – otherwise, there would be no Gazans.' US President Donald Trump on Monday said he disagreed with Netanyahu's claim of no starvation, noting the images emerging of emaciated people: 'Those children look very hungry.' After international pressure, Israel at the weekend announced humanitarian pauses, airdrops and other measures meant to allow more aid to Palestinians in Gaza. But people there say little or nothing has changed on the ground. The UN has described it as a one-week scale-up of aid, and Israel has not said how long the latest measures will last. 'This aid, delivered in this way, is an insult to the Palestinian people,' said Hasan Al-Zalaan, who was at the site of an airdrop as some fought over the supplies, and crushed cans of chickpeas littered the ground. Israel asserts that Hamas is the reason aid isn't reaching Palestinians in Gaza and accuses its militants of siphoning off aid to support its rule in the territory. The UN denies that the looting of aid is systematic and that it lessens or ends entirely when enough aid is allowed to enter Gaza. Here's what we know. Deaths are increasing The World Health Organisation said on Sunday there had been 63 malnutrition-related deaths in Gaza this month, including 24 children under the age of five – up from 11 deaths total the previous six months of the year.

Sydney Morning Herald
16 hours ago
- Sydney Morning Herald
Ozempic drugmaker just became a victim of its own success
It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.

The Age
16 hours ago
- The Age
Ozempic drugmaker just became a victim of its own success
It seems counterintuitive, if not implausible, that a company which has revolutionised Western health and promises to potentially eradicate the insidious plague of obesity and address diabetes can be failing to meet its profit and sales expectations. But that is the dilemma faced by Ozempic and Wegovy maker Novo Nordisk. Its share price is shedding value faster than patients are shedding kilos. For blame, one need look no further than pirates and the president (Trump, of course). Novo Nordisk stunned investors on Wednesday by downgrading its earnings expectations, losing nearly a third of its share price at one point during the day's trading – that's $143 billion in value that evaporated in a couple of hours. For some context: there are plenty of spectacular drugs and treatments that have been developed over recent decades to address many of the world's serious health issues, from cancer to heart disease, but this drug tackles obesity and therefore the myriad other health conditions that stem from being overweight (such as stroke, osteoarthritis, heart disease and even some cancers). As such, it is a game-changer. These semaglutide drugs became so popular after their efficacy for weight loss became apparent that in a sense they became victims of their own success. According to the World Health Organisation, about one billion people around the globe are obese, which means the addressable market for this drug is beyond huge and skewed to Western (and therefore wealthier) economies. And that market is still growing. The number of people afflicted by obesity has doubled over the past 30 years in adults, and quadrupled in children and adolescents, the WHO says.